TS 33

Drug Profile

TS 33

Latest Information Update: 30 Mar 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fournier Pharma
  • Class Hormonal replacements
  • Mechanism of Action DNA-directed RNA polymerase stimulants; Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 30 Mar 2001 Discontinued-I for Menopausal syndrome in France (Transdermal)
  • 30 Mar 2001 Discontinued-I for Postmenopausal osteoporosis in France (Transdermal)
  • 21 Jun 2000 Ares-Serono is now called Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top